Evidence map›Paper›PMID 34547052›Full record

ArticlePloS one2021

Roadmap for the use of base editors to decipher drug mechanism of action.

Estel Aparicio-Prat, Dong Yan, Marco Mariotti, Michael Bassik, Gaelen Hess, Jean-Philippe Fortin, Andrea Weston, Hualin S Xi, Robert Stanton

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Estel Aparicio-PratSimulation and Modelling Sciences, Pfizer, Cambridge, Massachusetts, United States of America.ORCID 0000-0003-4477-5839
Dong YanInternal Medicine Research Unit, Pfizer, Cambridge, Massachusetts, United States of America.
Marco MariottiDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Michael BassikDepartment of Genetics, Stanford University, Palo Alto, California, United States of America.
Gaelen HessDepartment of Genetics, Stanford University, Palo Alto, California, United States of America.
Jean-Philippe FortinInternal Medicine Research Unit, Pfizer, Cambridge, Massachusetts, United States of America.
Andrea WestonDiscovery Sciences, Pfizer, Groton, Connecticut, United States of America.
Hualin S XiSimulation and Modelling Sciences, Pfizer, Cambridge, Massachusetts, United States of America.
Robert StantonSimulation and Modelling Sciences, Pfizer, Cambridge, Massachusetts, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR base editors are powerful tools for large-scale mutagenesis studies. This kind of approach can elucidate the mechanism of action of compounds, a key process in drug discovery. Here, we explore the utility of base editors in an early drug discovery context focusing on G-protein coupled receptors. A pooled mutagenesis screening framework was set up based on a modified version of the CRISPR-X base editor system. We determine optimized experimental conditions for mutagenesis where sgRNAs are delivered by cell transfection or viral infection over extended time periods (>14 days), resulting in high mutagenesis produced in a short region located at -4/+8 nucleotides with respect to the sgRNA match. The β2 Adrenergic Receptor (B2AR) was targeted in this way employing a 6xCRE-mCherry reporter system to monitor its response to isoproterenol. The results of our screening indicate that residue 184 of B2AR is crucial for its activation. Based on our experience, we outline the crucial points to consider when designing and performing CRISPR-based pooled mutagenesis screening, including the typical technical hurdles encountered when studying compound pharmacology.

Indexed as

CRISPR-Cas SystemsGene EditingGenes, ReporterHEK293 CellsHumansIsoproterenolLuminescent ProteinsMutagenesis, Site-DirectedReceptors, Adrenergic, beta-2RNA, Guide, CRISPR-Cas SystemsRNA InterferenceRNA, Small InterferingIsoproterenolLuminescent ProteinsReceptors, Adrenergic, beta-2RNA, Guide, CRISPR-Cas SystemsRNA, Small Interfering

Identifiers

PMID34547052
PMCPMC8454938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.